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Abstract
Two synthetic aziridinomitosenes (AZMs), Me-AZM and H-AZM, structurally related to mitomycin C (MC)
were evaluated for their anticancer activity against six cancer cell lines (HeLa, Jurkat, T47D, HepG2, HL-60,
and HuT-78) and tested for their DNA-modifying abilities in Jurkat cells. Cytotoxicity assays showed that MeAZM is up to 72-fold and 520-fold more potent than MC and H-AZM, respectively. Me-AZM also
demonstrated increased DNA modification over MC and H-AZM in alkaline COMET and Hoechst
fluorescence assays that measured crosslinks in cellular DNA. Me-AZM and H-AZM treatment of Jurkat cells
was found to sponsor significant DNA-protein crosslinks using a K-SDS assay. The results clearly indicate that
the AZM C6/C7 substitution pattern plays an important role in drug activity and supports both DNA-DNA and
DNA-protein adduct formation as mechanisms for inducing cytotoxic effects.
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Abbreviations
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1. Introduction
DNA-modifying agents are an important and valuable class of drugs used in conventional chemotherapy.
Mitomycin C (MC, see Figure 1), a natural product first isolated from the soil bacteria Streptomyces
caespitosus,1 is a member of this class and has historically had a role in the treatment of a number of cancers,
including colorectal, gastric, bladder, lung, head and neck, and non-small-cell lung cancers.2,3 MC requires
intracellular activation by diaphorase,4 cytochrome P450 reductase,5 or other 1- or 2-electron reductases,6 to
form MC-leucoaziridinomitosene (Figure 1), the fate of which depends upon the activation conditions. Under
conditions of fast MC reduction, low concentration, and acidic pH, bifunctional activation of the MCleucoaziridinomitosene is favored,7 which exerts antitumor effects through creation of DNA interstrand
crosslinks (ICLs) that prevent DNA replication and cause cell death.8,9 The sequence involves acid-catalyzed
aziridine ring opening of the MC-leucoaziridinomitosene to form an initial leucoaziridinomitosene-DNA
monoadduct. Ensuing carbamate departure and subsequent nucleophilic attack, followed by oxidation, results in
the MC-DNA ICL structure.
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Figure 1. Mechanism for MC activation that results in DNA ICLs (via bifunctional activation pathway) and DNA monoadducts (via
monofunctional activation pathway).

Under conditions of slow MC reduction, high drug concentration, or higher pH, the hydroquinone moiety in the
leucoaziridinomitosene re-oxidizes to yield the MC-AZM quinone structure that undergoes monofunctional
activation (Figure 1).7,10,11 MC-AZM is proposed to primarily cause DNA monoalkylation at C1 through acidactivation to produce a protonated aziridine that ring opens to relieve the strain associated with the threemembered ring.12 The presence of the adjacent electron deficient quinone moiety in the MC-DNA monoadduct
disfavors expulsion of the C10 carbamate group that is necessary to create the ICL. Further, the location of the
MC-DNA monoadduct within the DNA minor groove is thought to sterically hinder additional enzymatic
reduction of the quinone ring, which is essential for carbamate departure.13-15
The mechanism of AZM-sponsored DNA monoalkylation is generally well accepted. However, in contrast to
previous AZM studies, the synthetic C6/C7 unsubstituted (1S,2S)-6-desmethyl(methylaziridino)mitosene (HAZM, Figure 2) was shown to crosslink DNA in the absence of an exogenous reductant.16 Instead, H-AZM bisalkylated self-complementary DNA with the 5'-d(CG) dinucleotide sequence as the minimum common element.
ICL production was optimal at pH 6 and overall yield increased with reaction time (up to 48 hours). H-AZM
treatment of duplex DNA containing the inverted 5'-d(GC) dinucleotide sequence resulted in no detectable ICL
product. Similarly, H-AZM treatment failed to crosslink DNA sequences where the dG residues were replaced

with 2'-deoxyinosines (dI) that lack the exocyclic C2 amino group in the purine ring. Thus, H-AZM appears to
mediate dG-dG nucleobase ICL in the minor groove of the DNA duplex, but via an as yet unknown mechanism.
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Figure 2. Structures of H-AZM and Me-AZM.

In a DNA footprinting/UvrABC nuclease assay used to examine H-AZM modification of a 129-base pair DNA
fragment, the autoradiogram displayed bands corresponding to DNA adducts with molecular weights higher
than the starting DNA fragment.17 Notably, one of the bands increased upon addition of the nuclease and,
consequently, it was speculated that H-AZM was facilitating the formation of covalent DNA-protein crosslinks
(DPCs). In the same experiments, an AZM derived from mitomycin A did not produce analogous adducts.
Besides this tentative evidence, to the best of our knowledge, there are no other literature reports of AZMs
forming DPCs. However, MC has been shown to facilitate the crosslinking of actin to DNA in human leukemia
and myeloma cells.18-20
In this study, we evaluate the cellular toxicity of H-AZM and its C6 methyl derivative Me-AZM (Figure 2).17
Cytotoxicity was tested against a panel of six different human cancer cell lines (3 adherent and 3 non-adherent)
using a resazurin reduction assay to evaluate cell viability and proliferation. Mechanistic studies were
performed to evaluate AZM-induced DNA interactions. Me-AZM- and H-AZM-treated Jurkat cancer cells
were analyzed by single cell gel electrophoresis (COMET), Hoechst 33342 staining, and K-SDS DNA-Protein
crosslinking assays to assess the formation of DNA-DNA and DNA-protein adducts.
2. Results/Discussion
2.1 Resazurin reduction assay and AZM stability
The cytotoxic effects of Me-AZM, H-AZM, and MC against cancer cell cultures were determined using a
resazurin reduction assay that follows the conversion of blue non-fluorescent resazurin to pink fluorescent
resorufin that occurs in healthy metabolically active cells.20,21 The antiproliferative effects of Me-AZM, HAZM, and MC against six human cancer cell lines are summarized in Table 1 (see supplemental content for
representative cytotoxicity profiles). All three compounds produced drug IC 50 values that ranged from low
nanomolar to low micromolar concentrations.
Table 1. Summary of drug antiproliferative effects.
Mean IC 50 (± SEM) (nM)a
Adherent/
MC
H-AZM
Me-AZM
Suspension
HeLa
Cervical Adenocarcinoma
Adherent
1,870 ± 372
6,208 ± 523
525 ± 242
HepG2
Hepatocellular Carcinoma
Adherent
2,937 ± 209
7,870 ± 701
342 ± 73
T47D
Breast Ductal Carcinoma
Adherent
16,970 ± 1,472
9,291 ± 1,516
225 ± 78
HL-60
Acute Promyelocytic Leukemia
Suspension
410 ± 86
2,033 ± 967
30 ±
5
HuT-78
Cutaneous T-Cell Lymphoma
Suspension
66 ± 33
131 ±
48
24 ± 16
Jurkat
T-Cell Leukemia
Suspension
578 ± 67
4,160 ± 530
8 ±
6
Jurkat
T-Cell Leukemia (hypoxic)
Suspension
303 ± 131
3,965 ± 527
4 ±
2
a
IC 50 values represent the mean (± SEM) of three independent experiments (with at least n = 3 for each experiment).
Cell line

Type

Me-AZM was at least 2.75 times more active than MC and at least 5.5 times more active than H-AZM against
every cell line. The difference was most notable in Jurkat cells, where Me-AZM was 72-fold more potent than
MC and 520-fold more potent than H-AZM. Overall, the quinone-unsubstituted H-AZM was the least toxic of
the three compounds, with IC 50 values that were typically 2- to 13-fold lower than those of MC, although it
showed greater activity against T47D cells. Also, the three compounds were not as effective against adherent
cancer cell lines, displaying activity that was in the low micromolar range for MC and H-AZM (IC 50 = 2-17
µM) and the sub-micromolar range for Me-AZM (IC 50 = 0.2-0.5 µM).
The increased potency of Me-AZM over MC and H-AZM may be due to presence of the methyl group at C6,
lack of a hydrophilic amine group at C7, and methylation of the aziridine ring that may improve the
electrophilic integrity of the AZM and stabilize the molecule for productive reactions with cellular nucleophiles.
Alternatively, evidence suggests that H-AZM is inherently more reactive than other AZMs, especially under
basic/nucleophilic conditions, and this may account for its decreased potency. For example, H-AZM was
reported to decompose to unidentifiable products in basic methanol solutions in a manner that was consistent
with 1,4-addition (i.e., Michael addition) of an oxygen nucleophile into the quinone ring.17 In analogous
experiments, AZMs derived from MC underwent only aziridine ring-opening.12 However, H-AZM was more
stable than the other tested compounds in neutral and mildly acidic methanolic solutions.17
To examine whether drug instability could explain the differences in drug IC50 results, the decomposition of
Me-AZM and H-AZM in cell culture media (DMEM + 10% FBS) was monitored via HPLC (see supplemental
content). The results indicate that H-AZM decomposes rapidly in culture media, with only 10% of the
compound remaining after 2 hours. In contrast, Me-AZM was more stable, with 90% of the compound
remaining after 2 hours. Further, chromatograms suggest AZMs decompose to large molecular weight
components that overlap with contents of the cell culture media. These results, taken together with the methanol
solvolysis experiments,17 suggest that H-AZM is more susceptible to base or nucleophile-mediated
decomposition that most likely occurs via nucleophilic addition at C6 and/or C7. Bionucleophiles (e.g., amino
acids, albumin, etc.) present in the cellular media probably sequester H-AZM before it reaches a significant
cellular target, thus mitigating its overall cytotoxicity.
Although Me-AZM was consistently more potent than MC, the resazurin reduction assays were conducted
under aerobic conditions. Given MC’s requirement for reductive activation and reported increased efficacy
against hypoxic cells,23 we evaluated the antiproliferative effects of Me-AZM, H-AZM, and MC against Jurkat
T-cell leukemia cells that were first incubated in a 95% N 2 /5% CO 2 environment and then in a hypoxic
chamber for the duration of the experiment. Under these conditions, a slight but statistically insignificant
increase in potency was observed for each compound. However, Me-AZM remained the most effective, with an
IC 50 that was approximately 75-fold more potent than MC, suggesting that Me-AZM is more cytotoxic than
MC regardless of the oxygen tension in the experiment.
2.2 Modified alkaline single cell gel electrophoresis (COMET) assay
A modified COMET assay was used to assess the ability of synthetic AZMs to form DNA crosslinks.24-27 The
assay investigates the extent of drug-induced DNA crosslinking in individual cells by visualizing and
quantifying DNA migration following exposure to DNA damaging agents.25 The study examined the
electrophoretic mobility of DNA from individual cells first treated with MC, Me-AZM, or H-AZM and then
subsequently treated with hydrogen peroxide. The hydrogen peroxide induces DNA strand breaks, which
increases the DNA’s electrophoretic mobility and results in the appearance of an elongated “tail” in the
electropherogram. Agents that sponsor DNA crosslinks prior to hydrogen peroxide exposure hinder migration

during electrophoresis due to increased DNA fragment size or alterations to DNA contour during migration
through agarose. This leads to a decreased tail length when compared to cells treated with hydrogen peroxide
alone.24,27 A smaller value for the “tail extent moment”, which is calculated by multiplying tail length by the
measured amount of DNA in the tail,24,25 is indicative of increased DNA interstrand, intrastrand, or DNAprotein crosslinks.

Figure 3. Representative fluorescent images of aerobic Jurkat cells following the modified alkaline COMET assay and SYBR green
staining. (A) Drug untreated cells: minimal DNA strand breaks control; (B) Drug untreated cells + H 2 O 2 : maximal DNA strand breaks
control; (C-E) MC, H-AZM, Me-AZM treated cells + H 2 O 2 . Homologous images for COMET assays performed under hypoxic
conditions can be found in supplemental content.

The COMET assay electropherograms show that 10 µM AZM treatment results in decreased DNA mobility
from peroxide induced strand breaks alone (Figure 3). In Jurkat cells under aerobic conditions, both AZMs
produced significant reductions in tail extent moments relative to the 100 µM H 2 O 2 treatment control. MeAZM and He-AZM treatment produced similar mean tail extent moments (0.26 ± 0.4 and 0.49 ± 0.07,
respectively), indicating that extensive DNA crosslinks had occurred (Figure 4). Under the same conditions,
MC produced a tail extent moment (96.0 ± 6.0) that was not statistically different from the 100 µM H 2 O 2
treatment control, indicating minimal DNA crosslinks. Under hypoxic conditions, Me-AZM and H-AZM
treatment continued to cause extensive DNA crosslinks (tail extent moments of 0.32 ± 0.29 and 3.6 ± 0.7,
respectively). However, MC treatment under hypoxic conditions resulted in a slight, but statistically significant
decrease in tail extent moment (87.0 ± 2.5). This result is consistent with literature reports indicating that the
extent of crosslinks detected by the COMET is highly dependent upon cell type and drug incubation time,28 and
high drug concentrations are often required to visualize substantial responses.24,25

Figure 4. Modified alkaline COMET assay of Jurkat cells. Tail extent moments are expressed as the mean ± SEM of two experiments
(n > 50 cells per treatment). * denotes ρ < 0.05 by two-way ANOVA, when compared to the matched (i.e., aerobic or hypoxic)
peroxide treatment control (Untx + 100 µM H 2 O 2 ). (Untx = no drug treatment, MC = mitomycin C treated cells, H-AZM and MeAZM = aziridinomitosene treated cells.)

2.3 Hoechst 33342 fluorescence assay
Prior investigations of DNA crosslinkage by synthetic AZMs were confined to demonstrations of adduct
formation with purified nucleic acids or oligonucleotides. The COMET assays described above do not
differentiate between DNA interstrand, intrastrand, or DNA-protein crosslinks. To further establish that AZMs
could form DNA ICLs in eukaryotic cellular environments, we evaluated DNA modification induced by MeAZM and H-AZM in Jurkat cell lines using a Hoechst 33342 fluorescence assay.29-31 When bound to double
stranded DNA (dsDNA), Hoechst dyes exhibit increased fluorescence compared to single stranded DNA
(ssDNA). The premise of the assay is that DNA crosslinks lead to increased retention of fluorescent Hoechst
dye compared to un-crosslinked DNA. Thermal denaturation followed by rapid cooling normally causes DNA
base pair mismatches that yield extensive regions of ssDNA with decreased Hoechst fluorescence. Covalent
DNA crosslinks act as anchor points, decreasing the level of base pair mismatches that occur following a series
of heat denaturation/rapid cooling processes. Thus, more heavily crosslinked DNA will exhibit increased
recovery of dsDNA character and retention of Hoechst fluorescence.29
In this study, Me-AZM treatment of Jurkat cells produced a significant increase in the amount of crosslinked
DNA when compared to similar treatment with MC or H-AZM (Figure 5). The amount of Me-AZM sponsored
crosslinks per DNA fragment was calculated at 0.55 ± 0.05 and 0.51 ± 0.02 for aerobic and hypoxic cells,
respectively. These values are 68-fold and 8-fold greater than the crosslinks per DNA fragment sponsored by
MC treatment. Consistent with our earlier observations, the effects of H-AZM treatment were more modest,
showing a 13-fold increased amount of crosslinked DNA relative to MC under aerobic conditions. Under
hypoxic conditions, H-AZM treatment did not produce a significant increase in crosslinked DNA relative to
MC treatment.

Figure 5. DNA-DNA crosslinks in AZM and MC treated Jurkat cell lines. Cellular DNA was isolated after treatment with 10 µM
MC, H-AZM, or Me-AZM, the crosslinks per DNA fragment were measured as a decrease in Hoechst 33342 – DNA fluorescence
relative to untreated cellular DNA. Data presented is the mean ± SEM of two experiments (n = 6). * denotes ρ < 0.05 by two-way
ANOVA when compared to the matched (i.e., aerobic or hypoxic) untreated control.

The Hoechst 33342 fluorescence assay results showed that Me-AZM and H-AZM treatment produced DNA
crosslinks in cells after one hour of treatment under aerobic conditions, whereas only Me-AZM crosslinked
DNA to a significant extent in an hypoxic environment. MC treatment under aerobic and anaerobic conditions
produced minimal DNA modification. These results are consistent with our earlier findings demonstrating that
Me-AZM is the most active DNA-modifying agent of the three compounds, and that hypoxia only minimally
alters the experimental outcome. Further, AZM-induced DNA ICL formation is consistent with previous reports
that demonstrated H-AZM treatment of purified DNA and oligonucleotides under non-reductive conditions
resulted in DNA-DNA crosslinks.16,17
For H-AZM, there is an apparent discrepancy between the COMET and Hoechst assays in that one shows
extensive DNA crosslinkage while the other does not. However, proteins are removed during the DNA isolation
process required for the Hoechst assay, which probably removes DNA containing DPCs from the isolated DNA.
With the COMET assay, the entire cell is examined under electrophoresis, so this experiment does not
distinguish between DNA ICLs or DPCs. Thus, if the majority of H-AZM produces DPCs, a reduced tail
moment on the COMET assay would be observed, but DNA crosslinks would be minimized in the Hoechst
assay.
2.4 K-SDS DNA-protein crosslinking assay
The K-SDS assay has been widely used to study drug sponsored DNA-protein crosslinks (DPCs). Previous
studies, employing the alkaline elution assay, have shown that MC induces DPCs in mammalian cells,18-20,32 but
no reports have demonstrated that AZMs induce DPCs in vitro. To determine the potential of AZMs to crosslink
DNA to protein we used an adaptation of the K-SDS assay first described by Zhitkovitch and Costa.33 Unlike
the alkaline elution assay, the K-SDS assay conditions cause disassociation of non-covalently bound DNA, and
selective salt precipitation of DNA-protein adducts to effectively allow separation and quantification of
covalent DNA-protein complexes.

Figure 6. K-SDS assay for DPCs in drug treated Jurkat cells. DPCs were isolated from Jurkat cells after 1.5 h treatment with saline
(Untx), 3 mM formaldehyde (FA,) or 100 μM concentrations of MC, H-AZM, or Me-AZM. Data is presented as the mean ± SEM of
three independent experiments (n=9). * denotes ρ < 0.05 by two-way ANOVA when compared to the matched aerobic or hypoxic
untreated control (no bracket) or when compared to reaction conditions for a given treatment (with bracket).

The K-SDS assay conducted under aerobic conditions demonstrated that 100 µM Me-AZM and H-AZM
treatment induced significant increases in DPCs (17-20%) relative to the untreated Jurkat cell control (Figure 6).
Treatment with 3 mM formaldehyde (FA), a known DNA-protein crosslinking agent, showed the highest %
DPC (53.2 ± 3.7 %). Cells treated with 100 μM MC did not show significant increases in DPC (7.8 ± 2.3 %)
formation relative to the untreated control (4.5 ± 1.5 %), indicating these are not the primary DNA
modifications sponsored by MC. Interestingly, DPC formation for Me-AZM (41.9 ± 5.7 %) was enhanced
under hypoxia. However, hypoxic conditions failed to significantly improve H-AZM and MC stimulated DPC,
which remained statistically equivalent to untreated control.
Previous DNA footprinting studies with H-AZM resulted in high molecular weight, low mobility bands that
were consistent with DPC formation during nuclease exposure in the assay.17 Since the K-SDS assay is specific
for detecting chemically induced DNA-protein adducts, our current results with Me-AZM and H-AZM provide
the first substantive evidence of an AZM sponsored DPC. The lack of significant DPC formation by MC
contradicts prior studies that report MC stimulated actin crosslinks to DNA.18 This may be due to the increased
specificity of this particular technique. The K-SDS assay was created for the sole purpose of detecting and
isolating DPCs produced by crosslinking agents in vivo,33 and is thought to be more stringent than the alkaline
elution method used in the previous study.18
In spite of its utility, the K-SDS assay does not discriminate between protein covalently bound to
monoalkylated DNA or crosslinked DNA. Additionally, the order of binding events is not readily apparent after
conclusion of the experiment. Additional experiments will be necessary to obtain these mechanistic details.
2.5 Potential mechanisms for AZM ICL and DPC formation
While the mechanism of DNA ICL and DPC formation by Me-AZM and H-AZM is currently unknown, we
envision two reasonable mechanisms that could account for their formation in tumor cells and in reactions with
DNA in the absence of reductant (Figure 7). The first, Path A, involves acidic activation of the C1 and C10
electrophilic sites. Rapid acid-catalyzed aziridine ring-opening results in a carbocation that is captured by
nucleophilic DNA in the minor groove. Next, slow carbamate departure forms an iminium intermediate that
undergoes a second nucleophilic addition to produce the ICL. The acidic activation mechanism is consistent
with previous studies demonstrating that H-AZM forms DNA ICLs best under acidic conditions (pH 6) with
long reaction times (up to 48 hours).16 Also, the acidic mechanism serves to rationalize the increased potency

and increased DNA-binding efficiency of Me-AZM in cellular systems, reported herein, since incorporation of
the electron donating methyl group should help stabilize the carbocations formed upon aziridine ring-opening
and carbamate departure. However, the mechanism is inconsistent with several important observations. First,
numerous AZMs with varying electronic properties have been reported in the literature, many of which are
more electron rich than H-AZM,12 and it seems that acidic activation to yield DNA ICLs should have been
observed with some of these AZMs. Second, the mechanism proposed in path A does not provide an obvious
route to account for the previously unobserved DPCs. Finally, we have evidence (unreported) that H-AZM
crosslinks synthetic DNA more efficiently than Me-AZM,34 which contradicts the proposed mechanism.
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Figure 7. Potential mechanisms for the AZM-induced formation of DNA ICLs and DPCs in absence of reductant. Two
reasonable mechanisms for the formation of DNA ICLs and DPCs include aziridine opening and carbamate departure via acidic
activation (Path A, top) and carbamate departure via nucleophilic activation (Path B, bottom). Enzymatic reduction (not shown) in a
manner analogous to MC may be occurring in cellular systems, but this does not explain the formation of adducts in absence of
reductant.

The nucleophilic activation mechanism (Figure 7, Path B) has the notable feature of agreeing with prior reports
indicating that carbamate departure and subsequent ICL formation requires either extreme acidic conditions (pH
< 5)35 or reductive activation.10 Also, the mechanism agrees with our own observations to a greater extent and
invokes the lack of quinone substitution, a key structural feature that is unique to these particular AZMs. In both
compounds, at least one of the quinone carbon atoms is unsubstituted, which renders the AZMs susceptible to
Michael addition at that position. Given this, the first step in the hypothesized mechanism involves the standard
acid catalyzed aziridine ring-opening and DNA monoadduct formation, typical of previously reported AZMs.
Next, Michael addition by media or a cellular nucleophile results in an intermediate that can tautomerize to a
leucoaziridinomitosene species (leuco-AZM) where carbamate expulsion and crosslink formation are favored.
Support for this mechanism is provided by the non-enzymatic activation of mitomycin A by thiols, which has
been proposed to follow a sequence that is initiated by nucleophilic attack at C7.36,37
Nucleophilic activation also provides a potential avenue for DPC formation, if the nucleophile facilitating
activation is a DNA-associated protein. Further, Michael addition into the quinone ring offers an explanation for
the decreased potency of H-AZM compared to Me-AZM. Structurally, H-AZM affords two quinone
electrophilic sites, since both C6 and C7 are unsubstituted. In contrast, Me-AZM presents only C7 as an
electrophilic center. Thus, H-AZM is expected to be a highly reactive Michael acceptor that is more prone to
nucleophilic sequestration by cell media or other bionucleophiles prior to DNA alkylation. Our HPLC
decomposition experiments support the increased sensitivity to nucleophiles, as the DMEM cell culture media
resulted in about 90% decomposition of H-AZM in about 2 hours, whereas Me-AZM resulted in only about
10% decomposition over the same period of time. Thus, the formation of ICLs and DPCs by both AZMs, along

with the rapid decomposition of H-AZM, are indicative of Path B as the more likely mechanism for DNA
adduct formation in absence of reductant.
3. Conclusion
Two synthetic AZMs, differing only by the presence or absence of a quinone ring methyl at C6, were examined
for their ability to modify human cellular DNA. While both Me-AZM and H-AZM demonstrated DNA
modification, Me-AZM exerted more potent antiproliferative effects against cancer cell lines that were
consistently better than the effects of MC. The results of the modified COMET assays, Hoechst fluorescence,
and K-SDS assays suggest that the antiproliferative effects could in part be attributed to drug sponsored DNA
damage that yield either ICLs and/or DPCs. It is noteworthy that Me-AZM treatment produced much stronger
antiproliferative effects and more DNA adducts than H-AZM. Potentially, H-AZM showed lesser effects
because the unsubstituted quinone ring is a more reactive target for nucleophilic addition, which renders it more
prone to decomposition and decreased half-life in the cellular environment or extracellular media. The methyl
group at C6 in Me-AZM may sterically hinder nucleophile accessibility to the quinone ring, thus improving the
half-life of the AZM by preventing non-productive reactions with other biomolecules outside the context of the
DNA. Future experiments will be directed towards determining the DNA alkylating abilities of additional AZM
analogs with chemical modification at the C6 and C7 positions, characterizing the DNA-AZM adducts that are
produced in reactions with DNA and DNA-associated proteins in both cell cultures and in cell-free
environments, and evaluating the role of quinone reduction in DNA crosslinking experiments.
4. Materials and Methods
4.1 Materials
Me-AZM and H-AZM were synthesized in our laboratory according to previously reported methods.17,38 MC
was purchased from Cayman Chemical (Ann Arbor, MI). Resazurin sodium salt was acquired from Acros
Organics (Fairlawn, New Jersey). Anhydrous dimethyl sulfoxide (DMSO) was obtained from Sigma (St. Louis,
MO). Hoechst 33342 and 10,000x SYBR Green were obtained from Invitrogen (Carlsbad, CA). HyClone
growth media (RPMI-1640 and Dulbecco’s Modified Eagles Medium (DMEM) and penicillin/streptomycin
were obtained from Thermo Scientific (Waltham, MA). Fetal Bovine Serum (FBS) was purchased from Fisher
Scientific (Hampton, NH). Ultracleen Tissue & Cells DNA Isolation Kit was obtained from Mo Bio
Laboratories Inc. (Carlsbad, CA). Proteinase K was purchased from AMRESCO (Solon, OH). The COMET
Assay Kit was purchased from Trevigen (Gaithersburg, MD).
4.2 Cell culture methods and drug stocks
Aerobic Conditions: Six different human cell lines were used to evaluate the potency of the AZMs and MC.
The three suspension (Jurkat, HUT-78, HL-60) and three adherent cancer cell lines (HeLa, T47D, HepG2) were
the generous gifts from Drs. Denise Wingett, Cheryl Jorcyk and Kristen Mitchell, all from Boise State
University. The Jurkat and T47D cells were cultured in RPM1-1640 supplemented with 10% fetal bovine serum
(FBS), penicillin (100 U/mL) and streptomycin (100 µg/mL) (pen/strep). HeLa and HepG2 cell lines were
grown in Dulbecco’s Modified Eagles Medium (DMEM) containing 10% FBS with pen/strep. HL-60 and HUT78 cell lines were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 20% FBS and
pen/strep. All cell lines were grown at 37 ºC in 5% CO 2 . Stock solutions of Me-AZM, H-AZM, and MC were
prepared in DMSO and stored at -80 ºC prior to use. The stock solutions were thawed, quickly diluted in sterile
nanopure water or 1x PBS to achieve working concentrations for experiments, and rapidly added to cells in
order to minimize decomposition prior to AZM delivery.

Hypoxic Conditions: To induce hypoxia, a method previously described by Wang et al. with minor
modifications was used.39 The appropriate number of cells were transferred to well-ventilated flat bottom T-25
culture flasks in a MIC-101 Modular Incubator Chamber (Billups-Rothberg, Inc., Del Mar, CA) that was
continuously purged with 95% N 2 /5% CO 2 for 15 min to effect complete gas exchange. The chamber was
sealed and the cells incubated for an additional hour at 37 °C. PBS used for Me-AZM, H-AZM, and MC drug
dilutions was sparged with 95% N 2 /5% CO 2 prior to addition of the appropriate compound. The AZMs and MC
were delivered to the cells by quickly breaking the seal of the anaerobic chamber and pipetting directly into the
flasks. The anaerobic chamber was resealed and purged for another 15 min with the 95% N 2 /5% CO 2 gas
mixture. The cells were incubated in the sealed anaerobic chamber at 37 °C for the time required for each given
experiment.
4.3 Resazurin reduction assay
Adherent cells were harvested at high confluency during log phase of growth. Briefly, cells were washed with
sterile PBS and trypsinized for 5 min. Cells were collected by centrifugation (150-250 xg /5 min) and
resuspended in the appropriate medium supplemented with FBS and 1% penicillin/streptomycin. Sterile 96-well
plates were seeded with 8,000 cells/well and then incubated for 24 h at 37 °C in 5% CO 2 . The media was
removed and replaced with fresh media containing dilutions of Me-AZM, H-AZM, MC, or vehicle to achieve
the desired concentration gradient. Suspension cell lines were also plated at 8,000 cells/well. After drug
addition, cells were incubated for an added 48 h, at which time 20 μL of 0.1% resazurin in sterile PBS was
added into each well and incubated for an additional 4-24 h at 37 °C in 5% CO 2 . Fluorescence values
(excitation/emission: 530/590 nm) were then obtained using a BioTek Synergy HT plate reader (BioTek,
Winooski, VT). Fluorescence data was plotted as a percentage of the untreated value using GraphPad Prism and
fit to a non-linear regression with log (inhibitor) vs. response for determination of IC 50 values. Data are
presented as the mean (± SEM) for at least three independent experiments with at least three replicate wells
used in each experiment.
4.4 Decomposition of Me-AZM and H-AZM in DMEM cell culture media
HPLC analysis was conducted using an Agilent 100 series HPLC equipped with a 50 mm x 4.6 mm with 5 μm
pore size hypersil GOLD phenyl column and detected at 254 and 480 nm. HPLC samples were prepared as
quickly as possible (ca. < 5 min) to minimize decomposition by adding Me-AZM and H-AZM stock solutions
in DMSO to filter-sterilized DMEM containing 10% FBS with pen/strep to yield a final concentration of 250
µM for Me-AZM and 250 µM for H-AZM. The solutions were vortexed, filtered into HPLC vials using 0.2
μM pore size PTFE syringe filters. The vials were placed in an auto-sampler and 20 μL of solution was injected
into the HPLC every 15 min until near complete decomposition was observed. HPLC-grade acetonitrile pH 7.2
Tris buffer were prepared as a mobile phase A and B, respectively. Gradients were conducted flow rate at 1.0
ml/min for 15 minutes with the following linear program: t= 0 min (30%; A, 70%; B), t= 10 min (70%; A, 30%;
B), t= 12 min (70%; A, 30%; B), t= 12.1 min (30%; A, 70%; B), and t= 15 min (30%; A, 70%; B). The HPLC
retention times for H-AZM and Me-AZM were 2.9 min and 6.6 min, respectively. Chromatograms are
included in the supplemental content.
4.4 Modified alkaline single cell gel electrophoresis (COMET) assay
The alkaline COMET Assay was performed according to the manufacturer’s protocol (Trevigen, Gaithersburg,
MD) with minor modifications. Briefly, Jurkat cells were harvested, washed once with complete RPMI-1640,
and reconstituted to a final density of 1 x 105 cells/mL. Cells were then either treated with a final concentration

of either 10 µM Me-AZM, H-AZM, MC, or 1x PBS for one hour at 37 °C in 5% CO 2 with agitation every 15
min. After one hour, the cells were harvested by centrifugation, washed once in 1x PBS, then resuspended in
100 µM hydrogen peroxide in 1x PBS for 20 minutes at 4 °C. After treatment, cells were harvested by
centrifugation at 4 °C (5 min, 150 xg), washed twice, and resuspended in 1 mL of 1x PBS. A 50 µL portion of
the cell suspension was combined with 500 μL of 37 °C low melting point agarose, and a 50 μL portion spread
evenly on the COMET slide. COMET slides were then allowed to solidify at 4 °C for 30 minutes in the dark,
and then were submerged in lysis solution overnight at 4 °C in the dark. Next, the slides were submerged in a
freshly prepared alkaline DNA unwinding solution (pH >13) for 20 min at 22 °C in the dark, and then subjected
to electrophoresis (20V, ~300 mA) for 30 min at 4 °C under minimal light conditions. The slides were
submerged in DI water twice (5 min), once (5 min) with 70% ethanol, dried at 37 °C for 15 min, and then
stained with 1x SYBR Green solution in 10 mM Tris, 1mM EDTA (pH 8.0) for 30 minutes at 22 °C in the dark.
Slides were then submerged into DI water to remove excess SYBR green and dried for 1-2 hours at 37 °C.
COMET slides were examined and images captured on an AMG Evos fluorescence microscope (Mill Creek,
WA) using the 10x objective and GFP filter. Analysis for tail extent moment was performed using the
OpenComet plugin for ImageJ (NIH),40,41 and tail extent moments (mean ± SEM) plotted in GraphPad Prism
using a minimum of 50 COMET analyses per drug treatment group from two experiments.
4.5 Hoechst 33342 fluorescence assay
The Hoechst fluorescence assay was adapted from a previously reported DNA crosslinking assay.29 Jurkat cells
(~5-6 x 106 cells) were treated with either 10 μM MC, Me-AZM, H-AZM or 1x PBS for 1 hour. DNA from
was then isolated using the Mo Bio Ultracleen Tissue & Cells DNA Isolation Kit according to the
manufacturer’s instructions. Samples for the assay were prepared in the dark by combining isolated cellular
DNA (3,750 ng) with 300 µL of 1.0 µg/mL Hoechst 33342 dye in nanopure H 2 O. The total volume was brought
to 3 mL with 0.5x TE buffer. Sample fluorescence was measured using an excitation/emission wavelength of
360/460 nm. A fluorescence control reaction consisted of 3 mL 0.5x TE buffer containing only 0.1 µg/mL
Hoechst 33342 dye. The retention of fluorescence was then measured after subjecting samples to a heat/chill
process as follows: 5 min in a 96-98 °C water bath, immediate chilling in an ice-water bath for 5 min, followed
by incubation in a room temperature water bath for 5 min. The fluorescence measurement was repeated and the
crosslinked fraction determined using Equation 1:
Cross-linked fraction =

𝐸𝐸𝐴𝐴
𝐸𝐸𝐵𝐵

𝐶𝐶
− 𝐴𝐴

1 −

𝐶𝐶𝐵𝐵
𝐶𝐶𝐴𝐴
𝐶𝐶𝐵𝐵

Equation 1

Where, C A = fluorescence of control sample after heat/chill, C B = fluorescence of control sample before heat
chill, E A = fluorescence of experimental sample after heat/chill, and E B = fluorescence of experimental sample
before heat/chill.
Crosslinked fraction values were converted to crosslinks per DNA fragment using Equation 2:

Crosslinks per DNA fragment = -ln(1-X)

Equation 2

Where X = the crosslinked fraction, as determined using Equation 1.
Data was analyzed in Microsoft Excel and GraphPad Prism. Values represent the mean (± SEM) of two
independent DNA isolations with measurements conducted in triplicate for each isolation.
4.6 K-SDS DNA-protein crosslinking assay
DNA-protein crosslinks were determined using a method adapted from Zhitkovitch and Costa.33 Briefly, Jurkat
cells (2 x 105 cells) were treated for 1.5 h at 37 °C in complete RPMI-1640 (for AZM and MC treatment) or
serum-free RPMI-1640 (for 3mM formaldehyde treatment). Two different AZM and MC drug concentrations,
10 μM and 100 μM, were used to show a concentration dependent increase in DPCs. After treatment, cells were
washed twice with ice-cold PBS, resuspended in 20 μL PBS, and then lysed by addition of 100 μL 2% SDS in
20mM Tris-HCl solution (pH 7.5). The lysed samples were then frozen at -20 °C. After thawing, samples were
vigorously vortexed for 10 s, warmed to 65 °C for 10 min and then 100 μL of a 200 mM KCl/20 mM Tris-HCl
(pH 7.5) solution was added. The DNA was sheared by passing each sample through a 200 µL pipet tip five
times. Samples for K-SDS precipitation were formed by chilling samples on ice for 5 min and collecting by
centrifugation at 3000 xg for 5 min. The supernatant from each sample was saved in individual microfuge tubes
and the pellets subjected to three rounds of precipitation: pellets were resuspended in 200 µL 100 mM KCl/20
mM Tris-HCl (pH 7.5), heated to 65 °C for 10 min, placed on ice for 5 min and centrifuged at 3000 xg for 5
min. The pellets were resuspended in 0.2 mg/mL proteinase K solution in 100 mM KCl/20 mM Tris-HCl (pH
7.5) and incubated at 55 °C for 3 h. After incubation, the samples were placed on ice for 10 min to allow the
precipitation of SDS. Samples were centrifuged at 10,000 xg for 10 min and the supernatants collected. The
quantity of protein-linked and non-linked DNA was measured using SYBR Green dye (Invitrogen, Carlsbad,
CA) and comparing fluorescence values against a known DNA standard. The percent DPC was calculated as %
DPC = [protein-linked DNA/(non-linked DNA + protein-linked DNA)] x 100%.
Supplementary data
Supplementary data (representative resazurin antiproliferative activity profiles, HPLC chromatograms obtained
as part of decomposition studies, and representative fluorescent images of anaerobic Jurkat cells following the
modified alkaline COMET assay and SYBR green staining) associated with this article can be found, in the
online version, at http://dx.doi.org.....
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